Your browser doesn't support javascript.
loading
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models.
Moquist, Philip N; Bovee, Tim D; Waight, Andrew B; Mitchell, Jamie A; Miyamoto, Jamie B; Mason, Marsha L; Emmerton, Kim K; Stevens, Nicole; Balasubramanian, Cindy; Simmons, Jessica K; Lyon, Robert P; Senter, Peter D; Doronina, Svetlana O.
Afiliação
  • Moquist PN; Seattle Genetics, Inc., Bothell, Washington. pmoquist@seagen.com.
  • Bovee TD; Seattle Genetics, Inc., Bothell, Washington.
  • Waight AB; Seattle Genetics, Inc., Bothell, Washington.
  • Mitchell JA; Seattle Genetics, Inc., Bothell, Washington.
  • Miyamoto JB; Seattle Genetics, Inc., Bothell, Washington.
  • Mason ML; Seattle Genetics, Inc., Bothell, Washington.
  • Emmerton KK; Seattle Genetics, Inc., Bothell, Washington.
  • Stevens N; Seattle Genetics, Inc., Bothell, Washington.
  • Balasubramanian C; Seattle Genetics, Inc., Bothell, Washington.
  • Simmons JK; Seattle Genetics, Inc., Bothell, Washington.
  • Lyon RP; Seattle Genetics, Inc., Bothell, Washington.
  • Senter PD; Seattle Genetics, Inc., Bothell, Washington.
  • Doronina SO; Seattle Genetics, Inc., Bothell, Washington.
Mol Cancer Ther ; 20(2): 320-328, 2021 02.
Article em En | MEDLINE | ID: mdl-33288628
ABSTRACT
Auristatins, a class of clinically validated anti-tubulin agents utilized as payloads in antibody-drug conjugates, are generally classified by their membrane permeability and the extent of cytotoxic bystander activity on neighboring cells after targeted delivery. The drugs typically fall within two categories membrane permeable monomethyl auristatin E-type molecules with high bystander activities and susceptibility to efflux pumps, or charged and less permeable monomethyl auristatin F (MMAF) analogs with low bystander activities and resistance to efflux pumps. Herein, we report the development of novel auristatins that combine the attributes of each class by having both bystander activity and cytotoxicity on multidrug-resistant (MDR+) cell lines. Structure-based design focused on the hydrophobic functionalization of the N-terminal N-methylvaline of the MMAF scaffold to increase cell permeability. The resulting structure-activity relationships of the new auristatins demonstrate that optimization of hydrophobicity and structure can lead to highly active free drugs and antibody-drug conjugates with in vivo bystander activities.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Aminobenzoatos Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Aminobenzoatos Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2021 Tipo de documento: Article